Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Oct;65(4):995-1006.
doi: 10.1086/302575.

Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors

Affiliations

Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors

J M Varley et al. Am J Hum Genet. 1999 Oct.

Abstract

We have analyzed a panel of 14 cases of childhood adrenocortical tumors unselected for family history and have identified germline TP53 mutations in >80%, making this the highest known incidence of a germline mutation in a tumor-suppressor gene in any cancer. The spectrum of germline TP53 mutations detected is remarkably limited. Analysis of tumor tissue for loss of constitutional heterozygosity, with respect to the germline mutant allele and the occurrence of other somatic TP53 mutations, indicates complex sequences of genetic events in a number of tumors. None of the families had cancer histories that conformed to the criteria for Li-Fraumeni syndrome, but, in some families, we were able to demonstrate that the mutation had been inherited. In these families there were gene carriers unaffected in their 40s and 50s, and there were others with relatively late-onset cancers. These data provide evidence that certain TP53 alleles confer relatively low penetrance for predisposition to the development of cancer, and they imply that deleterious TP53 mutations may be more frequent in the population than has been estimated previously. Our findings have considerable implications for the clinical management of children with andrenocortical tumors and their parents, in terms of both genetic testing and the early detection and treatment of tumors.

PubMed Disclaimer

Figures

Figure  1
Figure 1
Diagrammatic interpretation of the somatic changes in tumors from patients 5 (a) and 8 (b).

References

Electronic-Database Information

    1. Online Mendelian Inheritance in Man (OMIM): http://www.ncbi.nlm.nih.gov/Omim (for ACC [MIM 201300])

References

    1. Bardeesy N, Falkoff D, Petruzzi M-J, Nowak N, Zabel B, Adam M, Aguiar MC, et al (1994) Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 7:91–97 - PubMed
    1. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, et al (1991) Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6:1699–1703 - PubMed
    1. Beroud C, Soussi T (1998) p53 gene mutations: software and database. Nucleic Acids Res 26:200–204 - PMC - PubMed
    1. Birch JM, Blair V, Kelsey AM, Evans DGR, Harris M, Tricker KJ, Varley JM (1998) Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 17:1061–1068 - PubMed
    1. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, et al (1994a) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54:1298–1304 - PubMed

MeSH terms

Associated data